文 献1）Hongo H, Kosaka T, Mizuno R, Ezaki T, Matsumoto K, Morita S, et al. Should we try antiandrogen withdrawal in castration-resistant prostate cancer patients? Insights from a retrospective study. Clin Genitourin Cancer 2016; 14: e569-e73.2）Kosaka T, Shinojima T, Morita S, Oya M. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Cancer Sci 2018; 109: 1570-5.3）Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 2015; 20: 1026-34.4）Hongo H, Kosaka T, Oya M. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer. Cancer Sci 2018; 109: 2937-45.5）Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, et al. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol 2019; 49: 766-71.進行性前立腺がんにおける薬剤耐性遺伝子発現ネットワークを標的とした新規リプログラミング療法6）Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K. Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. Can Sci 2013; 104: 1017-26.7）Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.8）Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.9）Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.87
元のページ ../index.html#101